Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
Follow GYRE
Gyre Therapeutics, Inc. (GYRE) Altman Z-score
Gyre Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 16.83, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 16.83 | (6.93) |
| FY2024 | 23.76 | (1.32) |
| FY2023 | 25.08 | (1.33) |
| FY2022 | 26.41 | 39.67 |
| FY2021 | −13.25 | (11.61) |
| FY2020 | −1.65 | (10.29) |
| FY2018 | 8.65 | 12.46 |
| FY2017 | −3.81 | 2.69 |
| FY2016 | −6.50 | (3.98) |
| FY2015 | −2.52 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.51 | — | 0.61 | |
| Retained earnings / total assets | (0.41) | — | −0.58 | |
| EBIT / total assets | 0.07 | — | 0.23 | |
| Market value of equity / total liabilities | 26.45 | — | 15.87 | |
| Sales / total assets | 0.70 | — | 0.70 | |
| Altman Z-score | Safe zone | 16.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.71 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GYRE Gyre Therapeutics, Inc. | 16.8× |
| MDXG MiMedx Group, Inc compare | 9.4× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 3.9× |
| OABI OmniAb, Inc. compare | 2.5× |
| CADL Candel Therapeutics, Inc. compare | −1.2× |
| PRME Prime Medicine, Inc. compare | −3.7× |
| DSGN Design Therapeutics, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
| AURA Aura Biosciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets